|
1.EA. M: World Cancer Report 2014: World Health Organization; 2014. 2.Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA: a cancer journal for clinicians 2014, 64(1):9-29. 3.中華民國100年癌症登記報告. In.: Health promotion administration, Ministry of Health and Welfare; 2011. 4.Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT: Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. International journal of cancer Journal international du cancer 2005, 113(3):475-482. 5.Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM: Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. Journal of the American College of Surgeons 2000, 190(5):562-572; discussion 572-563. 6.Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U: Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Annals of surgery 2001, 234(3):360-367; discussion 368-369. 7.Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. International journal of cancer Journal international du cancer 2001, 94(2):153-156. 8.Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, Group EGW: Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013, 24 Suppl 6:vi51-56. 9.Williams CD: Antioxidants and prevention of gastrointestinal cancers. Current opinion in gastroenterology 2013, 29(2):195-200. 10.Pennathur A, Gibson MK, Jobe BA, Luketich JD: Oesophageal carcinoma. Lancet 2013, 381(9864):400-412. 11.Huang Q, Luo K, Yang H, Wen J, Zhang S, Li J, Ela Bella A, Liu Q, Yang F, Zheng Y et al: Impact of alcohol consumption on survival in patients with esophageal carcinoma: a large cohort with long-term follow-up. Cancer science 2014, 105(12):1638-1646. 12.Lin S, Wang X, Huang C, Liu X, Zhao J, Yu IT, Christiani DC: Consumption of salted meat and its interactions with alcohol drinking and tobacco smoking on esophageal squamous-cell carcinoma. International journal of cancer Journal international du cancer 2015, 137(3):582-589. 13.Rice TW, Rusch VW, Ishwaran H, Blackstone EH, Worldwide Esophageal Cancer C: Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116(16):3763-3773. 14.Roth MJ, Hu N, Emmert-Buck MR, Wang QH, Dawsey SM, Li G, Guo WJ, Zhang YZ, Taylor PR: Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma. Cancer research 2001, 61(10):4098-4104. 15.Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends in genetics : TIG 2000, 16(4):168-174. 16.Wu DL, Sui FY, Jiang XM, Jiang XH: Methylation in esophageal carcinogenesis. World journal of gastroenterology : WJG 2006, 12(43):6933-6940. 17.Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, Lu PJ, Chang WL, Lai WW, Wang YC: Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. International journal of medical sciences 2014, 11(8):779-787. 18.Lima SC, Hernandez-Vargas H, Simao T, Durand G, Kruel CD, Le Calvez-Kelm F, Ribeiro Pinto LF, Herceg Z: Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics : official journal of the DNA Methylation Society 2011, 6(10):1217-1227. 19.Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 2009, 119(6):1420-1428. 20.Gurzu S, Turdean S, Kovecsi A, Contac AO, Jung I: Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World journal of clinical cases 2015, 3(5):393-404. 21.Nakaya Y, Sheng G: Epithelial to mesenchymal transition during gastrulation: an embryological view. Development, growth &; differentiation 2008, 50(9):755-766. 22.Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F et al: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn''s disease. Inflammatory bowel diseases 2008, 14(11):1514-1527. 23.Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer 2002, 2(6):442-454. 24.Brackenbury R, Rutishauser U, Edelman GM: Distinct calcium-independent and calcium-dependent adhesion systems of chicken embryo cells. Proceedings of the National Academy of Sciences of the United States of America 1981, 78(1):387-391. 25.Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, van Eijk R, Eilers PH, van de Water B, Cornelisse CJ et al: E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. British journal of cancer 2006, 94(5):661-671. 26.Yates CC, Shepard CR, Stolz DB, Wells A: Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. British journal of cancer 2007, 96(8):1246-1252. 27.Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA, Cano A: Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. Journal of cell science 2004, 117(Pt 13):2827-2839. 28.Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK et al: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 2013, 19(1):279-290. 29.Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer 2009, 9(4):265-273. 30.Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751. 31.Pang L, Li Q, Wei C, Zou H, Li S, Cao W, He J, Zhou Y, Ju X, Lan J et al: TGF-beta1/Smad signaling pathway regulates epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: in vitro and clinical analyses of cell lines and nomadic Kazakh patients from northwest Xinjiang, China. PloS one 2014, 9(12):e112300. 32.Iacobuzio-Donahue CA: Epigenetic changes in cancer. Annual review of pathology 2009, 4:229-249. 33.Smith ZD, Meissner A: DNA methylation: roles in mammalian development. Nature reviews Genetics 2013, 14(3):204-220. 34.Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S: Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. The EMBO journal 2002, 21(15):4183-4195. 35.Bird A: DNA methylation patterns and epigenetic memory. Genes &; development 2002, 16(1):6-21. 36.Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nature reviews Genetics 2008, 9(6):465-476. 37.Jabbari K, Bernardi G: Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene 2004, 333:143-149. 38.Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70. 39.Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 40.Herman JG, Baylin SB: Promoter-region hypermethylation and gene silencing in human cancer. Current topics in microbiology and immunology 2000, 249:35-54. 41.Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300(5618):455. 42.SB B: Stem cells, cancer, and epigenetics.: Cambridge (MA): Harvard Stem Cell Institute; 2008-2009. 43.Hermann A, Gowher H, Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cellular and molecular life sciences : CMLS 2004, 61(19-20):2571-2587. 44.Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG: The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011, 117(4):677-687. 45.Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20(24):3139-3155. 46.Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301(5895):89-92. 47.Sherr CJ: Principles of tumor suppression. Cell 2004, 116(2):235-246. 48.Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer science 2003, 94(7):575-581. 49.Kaestner KH, Knochel W, Martinez DE: Unified nomenclature for the winged helix/forkhead transcription factors. Genes &; development 2000, 14(2):142-146. 50.Friedman JR, Kaestner KH: The Foxa family of transcription factors in development and metabolism. Cellular and molecular life sciences : CMLS 2006, 63(19-20):2317-2328. 51.Lee CS, Friedman JR, Fulmer JT, Kaestner KH: The initiation of liver development is dependent on Foxa transcription factors. Nature 2005, 435(7044):944-947. 52.Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH: Foxa2 is required for the differentiation of pancreatic alpha-cells. Developmental biology 2005, 278(2):484-495. 53.Wan H, Kaestner KH, Ang SL, Ikegami M, Finkelman FD, Stahlman MT, Fulkerson PC, Rothenberg ME, Whitsett JA: Foxa2 regulates alveolarization and goblet cell hyperplasia. Development 2004, 131(4):953-964. 54.Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH: Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24(56):8277-8290. 55.Song Y, Washington MK, Crawford HC: Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer research 2010, 70(5):2115-2125. 56.Tang Y, Shu G, Yuan X, Jing N, Song J: FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell research 2011, 21(2):316-326. 57.Lehner F, Kulik U, Klempnauer J, Borlak J: The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007, 21(7):1445-1462. 58.Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ: Expression and role of Foxa proteins in prostate cancer. The Prostate 2006, 66(10):1013-1028. 59.Halmos B, Basseres DS, Monti S, D''Alo F, Dayaram T, Ferenczi K, Wouters BJ, Huettner CS, Golub TR, Tenen DG: A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer research 2004, 64(12):4137-4147. 60.Basseres DS, D''Alo F, Yeap BY, Lowenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG et al: Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung cancer 2012, 77(1):31-37. 61.Correction: Role of Transforming Growth Factor (beta) in Human Disease. The New England journal of medicine 2000, 343(3):228. 62.Akhurst RJ, Lehnert SA, Faissner A, Duffie E: TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990, 108(4):645-656. 63.Penn JW, Grobbelaar AO, Rolfe KJ: The role of the TGF-beta family in wound healing, burns and scarring: a review. International journal of burns and trauma 2012, 2(1):18-28. 64.Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine &; growth factor reviews 1997, 8(1):21-43. 65.Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annual review of immunology 2006, 24:99-146. 66.Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH: TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nature cell biology 2002, 4(1):51-58. 67.Sinha S, Nevett C, Shuttleworth CA, Kielty CM: Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix biology : journal of the International Society for Matrix Biology 1998, 17(8-9):529-545. 68.Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell research 2009, 19(2):156-172. 69.Pardali K, Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et biophysica acta 2007, 1775(1):21-62. 70.Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S: Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. Journal of experimental &; clinical cancer research : CR 2003, 22(2):315-320. 71.Lee JD, Hempel N, Lee NY, Blobe GC: The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis 2010, 31(2):175-183. 72.Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425(6958):577-584. 73.Jung SM, Lee JH, Park J, Oh YS, Lee SK, Park JS, Lee YS, Kim JH, Lee JY, Bae YS et al: Smad6 inhibits non-canonical TGF-beta1 signalling by recruiting the deubiquitinase A20 to TRAF6. Nature communications 2013, 4:2562. 74.Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1999, 13(15):2105-2124. 75.Lee C, Zhang Q, Zi X, Dash A, Soares MB, Rahmatpanah F, Jia Z, McClelland M, Mercola D: TGF-beta mediated DNA methylation in prostate cancer. Translational andrology and urology 2012, 1(2):78-88. 76.Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, Fang JY: Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. The Journal of biological chemistry 2007, 282(16):12249-12259. 77.Bu F, Liu X, Li J, Chen S, Tong X, Ma C, Mao H, Pan F, Li X, Chen B et al: TGF-beta1 induces epigenetic silence of TIP30 to promote tumor metastasis in esophageal carcinoma. Oncotarget 2015, 6(4):2120-2133. 78.Geback T, Schulz MM, Koumoutsakos P, Detmar M: TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques 2009, 46(4):265-274. 79.Si HX, Tsao SW, Lam KY, Srivastava G, Liu Y, Wong YC, Shen ZY, Cheung AL: E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer letters 2001, 173(1):71-78. 80.Zhang Y, Handley D, Kaplan T, Yu H, Bais AS, Richards T, Pandit KV, Zeng Q, Benos PV, Friedman N et al: High throughput determination of TGFbeta1/SMAD3 targets in A549 lung epithelial cells. PloS one 2011, 6(5):e20319. 81.Lin CS, Lee HT, Lee SY, Shen YA, Wang LS, Chen YJ, Wei YH: High mitochondrial DNA copy number and bioenergetic function are associated with tumor invasion of esophageal squamous cell carcinoma cell lines. International journal of molecular sciences 2012, 13(9):11228-11246. 82.Schuster N, Krieglstein K: Mechanisms of TGF-beta-mediated apoptosis. Cell and tissue research 2002, 307(1):1-14. 83.Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nature cell biology 2000, 2(2):84-89. 84.Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer research 2002, 62(6):1613-1618. 85.Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7):927-939. 86.Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, Muller CA, Kalluri R, Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nature medicine 2010, 16(5):544-550. 87.You H, Ding W, Rountree CB: Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51(5):1635-1644.
|